Centre Hospitalier De Dax Cote D'Argent

Dax 22 trials 12 recruiting

22 Registered trials

12 Currently recruiting

Organisation

Centre Hospitalier De Dax Cote D'Argent

Location

Dax, France

Identifier

ORG-100046549

Address

Boulevard Yves Du Manoir, 40100, France

Departments

Centre Hospitalier de Dax - Service de Rhumatologie
Intensive Care Unit
Internal medicine
Médecine Interne
Médecine interne et immuno-hématologie
Multipurpose intensive care
Neurology
Oncologie médicale
oncology
Pneumologie et Radiothérapie - Oncologie
Radiotherapy
Réanimation
Rheumatology
Rhumatologie
Surgery

Clinical trials at this site (22)

Search interface

MAINRITSys : Rituximab vs placebo for maintenance in systemic sclerosis – interstitial lung disease Pending

2025-521331-36-00 Patient with stabilized SSc-ILD (as defined by a declin 10
Study evaluating two treatment strategies for rectal cancer in patients ≥75 years old Pending

2025-521619-37-00 Patients ≥75 years old with cT3/T4 rectal adenocarcinom 5
PREP-ANCA - Comparison of a strategy based on clinic-biological surveillance versus pre-emptive treatment with rituximab in the event of ANC… Pending

2025-522049-23-00 granulomatosis with polyangiitis and microscopic polyan 6
Lessening Organ Dysfunction with VITamin C in septic ARDS Recruiting

2024-516394-78-00 Patient with sepsis complicated by ARDS 5 2024-11-05
CPAAARI-Therapeutic efficacy comparison of a six-month treatment by itraconazole and nebulised Ambisome® versus treatment by itraconazole al… Recruiting

2024-517004-11-00 Chronic pulmonary aspergillosis 5 2024-10-22
AZD5335 vs. Mirvetuximab Soravtansine in FRα-high and AZD5335 vs. Chemotherapy in FRα-low Platinum-resistant Ovarian Cancer (TREVI-OC-01) Recruiting

2025-520466-22-00 Advanced Platinum-resistant Epithelial Ovarian Cancer 5 2026-04-29
Apneic oxygenation with high-flow nasal oxygenation after preoxygenation with noninvasive ventilation before intubation in hypoxemic patient… Recruiting

2024-514949-11-00 Hypoxemic acute respiratory failure 5 2026-03-18
OBI-WAN : Obinutuzumab for remission induction in patients with relapsing PR3-ANCA granulomatosis with polyangiitis (Wegener’s). Phase 2 pro… Recruiting

2022-501557-36-00 PR3-ANCA granulomatosis with polyangiitis (Wegener’s) 4 2025-12-19
Strategies for zoledronic acid post-denosumab discontinuation in postmenopausal osteoporosis Recruiting

2024-511871-13-00 Postmenopausal osteoporosis 6 2025-10-02
Combination of baricitinib and anti-TNF in rheumatoid arthritis Recruiting

2024-511442-39-00 Rheumatoid arthritis (RA) 5 2025-02-05
PRODIGE 70 - CIRCULATE - CIRCULATING TUMOR DNA BASED DECISION FOR ADJUVANT TREATMENT IN COLON CANCER STAGE II Recruiting

2024-515297-27-00 colon carcinoma 5 2024-08-14
UVB: treatment of UVeitis in Behçet’s diseases with biologic Recruiting

2024-513371-41-00 Severe uveitis of Behçet’s disease 4 2024-04-25
CARE1: FIRST LINE RANDOMISED STUDY PLATFORM TO OPTIMIZE TREATMENT IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA Recruiting

2023-503317-29-00 Metastatic renal cell carcinoma (mRCC) 5 2024-04-12
Weaning protocol for high-flow nasal oxygen therapy in the ICU - Multicenter randomized controlled trial. HiFloWEAN Recruiting

2023-504366-36-00 de novo acute respiratory failure 5 2024-02-17
RIISC Recruiting

2024-513669-38-00 Stroke, Ischemic, TIA, Cardiac Disease, Atherosclerosis 5 2023-05-17
TocilizuMab discontinuAtion in GIant Cell Arteritis Ended

2023-505515-21-00 Giant Cell Arteritis 5 2024-04-02
PRODIGE 85 (FFCD 1804) – KANALRAD Prospective randomized phase III study evaluating induction chemotherapy (modified DCF 4 cycles) followed… Ended

2023-505972-32-00 locally advanced anal squamous cell carcinoma 5 2024-02-26
MEthotrexate versus TOcilizumab for treatment of GIant cell Arteritis: a multicenter, randomized, controlled trial Ended

2024-512269-14-00 GIant cell Arteritis 5 2020-01-27
Salvage Therapy for Patients with Inadequate Response to Standard of Care Therapy in Granulomatosis with Polyangiitis Halted

2024-516687-28-00 Patients with GPA and inadequate response to standard o 5 2025-06-06
SCLERITA - Safety and efficacy of itacitinib in adults with systemic sclerosis: a phase II, randomized, controlled trial Ended

2024-513648-27-00 Patients with newly or active diffuse Systemic sclerosi 4 2024-10-25
A Ph2 dose-finding study (MARS-17) to evaluate the efficacy and safety of GSK3858279 in adults with knee osteoarthritis pain. Ended

2022-502799-22-00 Knee osteoarthritis pain 4 2023-11-29
Treatment of non severe Hemophagocytosis Lymphohistiocytosis with ITACITINIB a Phase II prospective trial Ended

2024-513173-44-00 Adults patients having non severe HLH 4 2022-05-03